Boehringer Ingelheim and G1 Therapeutics have announced that the injection of COSELA™ (trilaciclib) is now commercially available in the US. COSELA, the only U.S. Food and Drug Administration (FDA)-approved treatment that is meant to decrease the incidence of chemotherapy-induced myelosuppression in adult patients. The drug therapy is designed to protect bone marrow when injected prior to chemotherapy treatment. Soma Gupta, Chief Commercial Officer at G1 Therapeutics, stated, “This is an exciting time for the combined G1 and Boehringer Ingelheim team as we are now able to provide COSELA, the first proactive multilineage myeloprotection therapy, to patients with extensive-stage small cell lung cancer.”
More on: News Regulatory